Drugs - MedicineNews.net - Medical Updates

Search results for "Breast cancer"

Longer median overall survival in postmenopausal HR+ / HER2- metastatic breast cancer patients treated with Ribociclib

Updated median overall survival ( OS ) results for Ribociclib ( Kisqali ) in combination with Fulvestrant ( Faslodex ) in postmenopausal women with hormone receptor positive, human epidermal growth fa ... read article

IMpower010: Atezolizumab improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care

The phase III IMpower010 study evaluating Atezolizumab ( Tecentriq ), compared with best supportive care ( BSC ), has met its primary endpoint of disease-free survival ( DFS ) at the interim analysis. ... read article

Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

The EMA's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Kadcyla ( Trastuzumab emtansine ) for the adjuvant treatment of adult patients with HER2-positive earl ... read article

Kisqali plus Fulvestrant in women with HR+/HER2- locally advanced or metastatic breast cancer

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending an expanded indication for Kisqali ( Ribociclib ), the ... read article

Lurbinectedin has shown noteworthy clinical activity in metastatic breast cancer with mutations in BRCA 1/2

Lurbinectedin ( Zepsyre ) has shown noteworthy clinical activity in patients with metastatic breast cancer that have mutations in the BRCA 1 and/or BRCA 2 genes. A phase II trial has assessed the c ... read article

Larotrectinib, a TRK inhibitor, in children and adults patients with NTRK fusion cancer

Larotrectinib is being investigated to potentially treat adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion ... read article

SOLAR-1 trial: alpha-specific PI3K inhibitor Alpelisib has met primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

The global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free survival ( ... read article

Tivozanib, a VEGF tyrosine kinase inhibitor, for the treatment of adult patients with advanced renal cell carcinoma

Tivozanib ( Fotivda ) is an oral, once-daily, vascular endothelial growth factor ( VEGF ) tyrosine kinase inhibitor ( TKI ) for the treatment of adult patients with advanced renal cell carcinoma ( RCC ... read article

HER2-positive breast cancer: Neratinib, little benefit and severe toxicity

The FDA ( U.S. Food and Drug Administration ) has approved 1 year of extended adjuvant Neratinib ( Nerlynx ) after chemotherapy and a year of Trastuzumab ( Herceptin ) for HER2-positive breast cancer ... read article

Advanced BRCA-related breast cancer: Olaparib, a PARP inhibitor, is superior to chemotherapy

During the American Society of Clinical Oncology ( ASCO ) Annual Meeting, the results of the phase III OlympiAD trial demonstrating for the first time that Olaparib ( Lynparza ) is superior to chemoth ... read article

Breast cancer may be more aggressive in patients with obesity

Women with obesity are more likely to get breast cancer, and a number of studies have provided a reasonable explanation why: after menopause, fat tissue manufactures estrogen, and the estrogen then pr ... read article

Capecitabine, an anticancer agent, associated with risk of severe skin reactions

Capecitabine ( Xeloda ) is a first-line, adjuvant, or combination treatment for colon cancer, and for metastatic colorectal cancer, gastric cancer, or breast cancer. Skin reactions associated with ... read article

European Commission: indication expansion of Halaven for advanced or metastatic breast cancer after only one prior chemotherapy

Eisai has announced that it has received approval from the European Commission ( EC ) of the indication expansion of Halaven ( Eribulin mesylate ) to contribute to earlier treatment of patients with l ... read article

New formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer

Roche has announced that a new injectable ( subcutaneous ) formulation of Herceptin ( Trastuzumab ) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an ag ... read article

Forxiga, a SGLT2 inhibitor, approved in Europe for treatment of type 2 diabetes

Forxiga ( Dapagliflozin ) is the first SGLT2 ( sodium/glucose cotransporter 2 ) class drug. Forxiga has obtained marketing approval by the European Commission ( EC ) for the treatment of type 2 diabet ... read article

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article

Castration-resistant prostate cancer: Cabozantinib linked to high rates of complete or partial bone scan resolution, pain relief, improvements in hemoglobin, and tumor regression

Exelixis has reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer ( CRPC ) treated with Cabozantinib ( XL184; Cometriq ) in an ongoing phase 2 ... read article